Sun Pharmaceutical Industries has announced a licensing agreement with Takeda Pharmaceutical Company to introduce a new gastrointestinal drug in India. Under this non-exclusive patent licensing pact, Sun Pharma will commercialize Vonoprazan tablets in 10 mg and 20 mg strengths across the country. Vonoprazan, a novel potassium competitive acid blocker (PCAB), is specifically designed to treat reflux esophagitis and other acid peptic disorders.
Kirti Ganorkar, CEO – India Business at Sun Pharma, expressed enthusiasm about the partnership, emphasizing Sun Pharma’s leadership in gastroenterology. He highlighted that bringing Vonoprazan to India aligns with their commitment to enhancing gastrointestinal health by offering patients and healthcare professionals a new therapeutic option.
Approved by the US FDA in November 2023, Vonoprazan is indicated for healing and maintenance of erosive esophagitis and for relieving associated heartburn. It is also approved for treating Helicobacter pylori (H. pylori) infection in combination with antibiotics.
Vonoprazan, developed by Takeda, has already received approval in India for use in adults suffering from reflux esophagitis and related acid peptic disorders.
As of the latest update, Sun Pharma’s shares were trading 0.69 percent higher at Rs 1,480.55 per share on the BSE.
